Navigation Links
Argos Therapeutics Files Registration Statement for Proposed Initial Public Offering
Date:7/29/2011

DURHAM, N.C., July 29, 2011 /PRNewswire/ -- Argos Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by the company.

Lazard Capital Markets LLC and Canaccord Genuity Inc. are acting as joint book-running managers for the offering.  Needham & Company, LLC and BMO Capital Markets Corp. are acting as co-managers.  

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This news release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction

The offering will be made only by means of a prospectus.  When available, copies of the preliminary prospectus relating to and describing the terms of the offering may be obtained from Lazard Capital Markets, Attn: Syndicate Department, 30 Rockefeller Plaza, 60th Floor, New York, NY 10020, phone: (800) 542-0970 or Canaccord Genuity, Attn: Syndicate Department, 99 High Street, 12th Floor, Boston, MA 02110, phone: (800) 225-6201.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV.

Contact:

Jeff Abbey
Argos Therapeutics
(919) 287-6308
jabbey@argostherapeutics.com


'/>"/>
SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Argos Therapeutics Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
2. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
3. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
4. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
5. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
6. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
7. Cell Therapeutics, Inc. (CTI) Reports Reduction in Operating Expenses and Net Losses for Second Quarter and First Half 2011 Compared to 2010, and Advances In Bringing Pixantrone to Market
8. Michael Showalter Joins Prime Therapeutics As Chief Marketing Officer
9. Chimerix to Present at Infocasts 9th Annual Biodefense Vaccines & Therapeutics Conference
10. Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market
11. Regulus Therapeutics Appoints Gregory Hannon, Ph.D. to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... 9, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... today announced it has earned a spot on ... The Company was ranked among 500 U.S. employers as ... Healthcare Equipment and Services. The annual ... anonymous, independent survey of over 30,000 employees across 25 ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
Breaking Medicine Technology:
(Date:5/19/2017)... CA (PRWEB) , ... May 19, 2017 , ... ... of the 2017 class of Beckman Young Investigators: , Victor Acosta, Ph.D. - ... - Cornell University, Dan Fu, Ph.D. - University of Washington, Erik Grumstrup, Ph.D. ...
(Date:5/19/2017)... ... May 19, 2017 , ... As a groundbreaking surgeon on the frontline ... prostate cancer screenings. Early detection of the disease, he says, can make a world ... Georgia Urology , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task ...
(Date:5/19/2017)... ... 18, 2017 , ... CloSYS products which are marketed as the gentle giants ... mouth and gum health, which is linked to one’s overall health. Since 1991 when ... the powerful ways in which CloSYS products immediately helped eliminate bad breath as well ...
(Date:5/19/2017)... ... May 18, 2017 , ... Somnoware, a leading provider of digital health technology, ... dispense CPAP devices and supplies, such as machines, filters, tubing, and masks. Using this ... Device registration for daily usage data is automated, and a DME order is created ...
(Date:5/18/2017)... ... May 18, 2017 , ... Originally launched to market as ... Learning Tab. Due to the rapid expansion of their product line, the company believed ... product. Now, the HighQ brand will be any tablet product sold by EPIK ...
Breaking Medicine News(10 mins):